Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus.

K Misstear, EA McNeela, AG Murphy, JA Geoghegan, KM O'Keeffe, J Fox, K Chan, S Heuking, N Collin, TJ Foster, RM McLoughlin, EC Lavelle

Research output: Contribution to journalArticlepeer-review


Despite showing promise in preclinical models, anti–Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellular-only response can protect against infection. We demonstrate that nasal vaccination with targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic S. aureus infection in the absence of any antigen-specific antibodies. These findings can help inform future developments in staphylococcal vaccine development and studies into the requirements for protective immunity against S. aureus.
Original languageEnglish
Pages (from-to)1479-1484
JournalThe Journal of Infectious Diseases
Issue number9
Publication statusPublished - May 2014


Dive into the research topics of 'Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus.'. Together they form a unique fingerprint.

Cite this